Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The medication Zeqmelit® is planned to be available in pharmacies in Sweden from September 1, 2024. Launches in Norway and Finland are expected to follow shortly thereafter. In parallel, pre-launch activities are underway to prepare the market for an effective launch.
AcuCort's medication Zeqmelit® - a fast-dissolving oral film placed on the tongue for the treatment of severe to acute allergy -is currently in an intensive commercialization phase. Based on extensive pre-launch activities, the planned launch will take place on September 1, 2024, making the product available to patients.
The launch plan stipulates that Zeqmelit® will be available in pharmacies in Sweden from 1 September, and in Norway and Finland shortly thereafter. In the meantime, pre-launch activities are being conducted with asthma and allergy specialists in the selected markets.
- It is very gratifying to announce the launch date and, most importantly, that patients will get access to Zeqmelit®, a much-needed medication. Our extensive pre-launch work, which has been ongoing for several months, will serve as a crucial foundation for the upcoming launch, says AcuCort's CEO Jonas Jönmark.
A large number of activities have been conducted during the pre-launch phase, with more planned. The ongoing Phase IV study ZEQ001 will provide significant support for the marketing efforts. The purpose of the study is to obtain valuable scientific data from patients who previously used tablets but are now using Zeqmelit®. This information will be used in the marketing of Zeqmelit® to doctors and healthcare professionals.
In line with the launch plan, our business partner Unimedic Pharma, together with AcuCort, has conducted a well-attended webinar for specialists in asthma and allergy.
AcuCort had previously communicated that Zeqmelit® could be launched during the summer of 2024. The reason why the planned launch date is now set for 1 September is due to a delay experienced by one of the subcontractors hired by our contract manufacturer. The delay is unrelated to the product itself and pertains to the package leaflet that accompanies the product's packaging, which is beyond AcuCort's control.
For further information:
Jonas Jönmark, CEO, AcuCort AB
Tel: +46 70 365 5400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.